alendronate has been researched along with Crohn Disease in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The question arises whether the absorption of alendronate, and thus its bioavailability, is further altered by the local inflammatory process in patients with Crohn's disease, thereby potentially affecting clinical outcome when used in the treatment of osteoporosis." | 3.73 | Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. ( Bänffer, D; Cremers, SC; den Hartigh, J; Hamdy, NA; Papapoulos, SE; van Hogezand, R; Vermeij, P, 2005) |
| "This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda." | 3.70 | Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. ( Badhwar, V; Campisi, P; Morin, S; Trudel, JL, 1999) |
| "Treatment with alendronate, 10 mg daily, significantly increased BMD in patients with Crohn's disease and was safe and well tolerated." | 2.69 | Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. ( Haderslev, KV; Sorensen, HA; Staun, M; Tjellesen, L, 2000) |
| " A random-effects model within a Bayesian framework was applied to compare treatment effects as standardized mean difference (SMD) with their corresponding 95% credible interval (CrI), while odds ratio (OR) was applied to compare adverse events with 95% CrI." | 2.55 | Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. ( Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, X | 1 |
| Zhou, C | 1 |
| Chen, H | 1 |
| Ma, J | 1 |
| Zhu, Y | 1 |
| Wang, P | 1 |
| Zhang, Y | 1 |
| Ma, H | 1 |
| Zhang, H | 1 |
| Tsujikawa, T | 1 |
| Andoh, A | 1 |
| Inatomi, O | 1 |
| Bamba, S | 1 |
| Nakahara, T | 1 |
| Sasaki, M | 1 |
| Saito, H | 1 |
| Fujiyama, Y | 1 |
| Cremers, SC | 1 |
| van Hogezand, R | 1 |
| Bänffer, D | 1 |
| den Hartigh, J | 1 |
| Vermeij, P | 1 |
| Papapoulos, SE | 1 |
| Hamdy, NA | 1 |
| Ornoy, A | 1 |
| Wajnberg, R | 1 |
| Diav-Citrin, O | 1 |
| Campisi, P | 1 |
| Badhwar, V | 1 |
| Morin, S | 1 |
| Trudel, JL | 1 |
| Haderslev, KV | 1 |
| Tjellesen, L | 1 |
| Sorensen, HA | 1 |
| Staun, M | 1 |
| Bailen, LS | 1 |
1 review available for alendronate and Crohn Disease
| Article | Year |
|---|---|
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic | 2017 |
2 trials available for alendronate and Crohn Disease
| Article | Year |
|---|---|
Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conserv | 2009 |
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
Topics: Adult; Alendronate; Biomarkers; Bone and Bones; Bone Density; Crohn Disease; Double-Blind Method; Fe | 2000 |
4 other studies available for alendronate and Crohn Disease
| Article | Year |
|---|---|
Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease.
Topics: Absorption; Administration, Oral; Alendronate; Biological Availability; Biomarkers; Bone Density; Bo | 2005 |
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi | 2006 |
Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.
Topics: Adult; Alendronate; Cathartics; Colectomy; Colonoscopy; Crohn Disease; Drug Combinations; Enema; Fem | 1999 |
Bones and Crohn's: should we treat Crohn's disease patients with alendronate?
Topics: Alendronate; Bone Density; Crohn Disease; Female; Humans; Male; Osteoporosis | 2001 |